Siegrist C-A
Centre for Vaccinology and Neonatal Immunology, University of Geneva, CMU, 1 Michel Servet, 1211 Geneva 4, Switzerland.
J Comp Pathol. 2007 Jul;137 Suppl 1:S4-9. doi: 10.1016/j.jcpa.2007.04.004. Epub 2007 Jun 7.
One of the major challenges in vaccinology is the development of products that are able to induce protective immunity in the early life period. There are clear differences between adult and neonatal immune responses in both mice and humans with respect to both humoral and cell-mediated immunity. As a rule, neonates respond poorly to T-independent polysaccharide antigens and make lower and less persistent antibody responses to T-dependent protein antigens. Nevertheless, B-cell priming in neonates may lead to the generation of memory B cells. Similarly, neonatal cell-mediated immune responses are of lower potency than those generated in adults, and a key factor underlying this phenomenon may be a less effective interaction between antigen and neonatal dendritic cells. In addition to immunological immaturity in the neonate, the presence of inhibitory concentrations of maternally derived antibody imposes a further barrier to effective early life vaccination. Novel vaccination strategies including early priming and subsequent boosting are most likely to counteract these effects and provide protection from exposure to infectious disease in early life.
疫苗学的主要挑战之一是研发能够在生命早期诱导保护性免疫的产品。在小鼠和人类中,成人和新生儿在体液免疫和细胞介导免疫方面的免疫反应存在明显差异。通常,新生儿对非T细胞依赖性多糖抗原反应较差,对T细胞依赖性蛋白质抗原产生的抗体反应较低且持续时间较短。然而,新生儿的B细胞致敏可能会导致记忆B细胞的产生。同样,新生儿的细胞介导免疫反应比成人产生的免疫反应效力更低,这一现象背后的关键因素可能是抗原与新生儿树突状细胞之间的相互作用效率较低。除了新生儿的免疫不成熟外,母源抗体抑制浓度的存在对有效的早期疫苗接种构成了进一步的障碍。包括早期致敏和随后加强免疫在内的新型疫苗接种策略最有可能抵消这些影响,并为早期生命免受传染病感染提供保护。